2014 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation

Canadian Journal of Cardiology

Volumn 30, Issue 10, 2014, Pages 1114-1130

  Verma, Atul ^a   Cairns, John A ^b   Mitchell, L Brent ^c   Macle, Laurent ^d   Stiell, Ian G ^e   Gladstone, David ^a   McMurtry, Michael Sean ^f   Connolly, Stuart ^g   Cox, Jafna L ^h   Dorian, Paul ⁱ   Ivers, Noah ^a   Leblanc, Kori ^j   Nattel, Stanley ^d   Healey, Jeff S ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^f UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIGOXIN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; TICLOPIDINE;

AMBULATORY MONITORING; ANTICOAGULANT THERAPY; ARTICLE; BASIC RESEARCH; CANADIAN; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY CARE; ENERGY RESOURCE; EVIDENCE BASED PRACTICE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART RATE; HEART RHYTHM; HEART SURGERY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT ATRIAL APPENDAGE CLOSURE; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MEDICAL INFORMATION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERICARDIAL DISEASE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RISK FACTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; ALGORITHM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CANADA; COMORBIDITY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE;

ALGORITHMS; ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CANADA; COMORBIDITY; ELECTRIC COUNTERSHOCK; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE; TICLOPIDINE;

EID: 84907965406     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.08.001     Document Type: Article

References (115)

1. Cairns J.A., Yusuf S., Cook R.J., et al. Canadian network and centre for trials internationally (cannectin): A national network for canadian-led trials in cardiovascular diseases and diabetes mellitus. Can J Cardiol 2010, 26:353-358.
2. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
3. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001, 285:2864-2870.
4. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
5. January CT, Wann LS, Alpert JS, etal. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation 2014 Apr 10. [Epub ahead of print].
6. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
7. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
8. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e531S-e575S.
9. Saposnik G., Gladstone D., Raptis R., Zhou L., Hart R.G. Atrial fibrillation in ischemic stroke: Predicting response to thrombolysis and clinical outcomes. Stroke 2013, 44:99-104.
10. Hart R.G., Pearce L.A., Aguilar M.I. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Int Med 2007, 147:590-592.
11. Aguilar M., Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005, CD001925.
12. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The atrial fibrillation investigators. Arch Intern Med 1997, 157:1237-1240.
13. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
14. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.
15. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
16. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
17. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
18. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2013, 369:2093-2104.
19. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383:955-962.
20. Lip G.Y., Larsen T.B., Skjoth F., Rasmussen L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. JAm Coll Cardiol 2012, 60:738-746.
21. Mantha S., Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012, 108:476-484.
22. Majeed A., Hwang H.G., Connolly S.J., et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013, 128:2325-2332.
23. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: . Accessed May 13,2014. http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm.
24. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013, 127:224-232.
25. 2-VASc score. Heart Rhythm 2012, 9:1755-1760.
26. 2-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013, 109:956-960.
27. Apostolakis S., Guo Y., Lane D.A., Buller H., Lip G.Y. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013, 34:3572-3579.
28. Banerjee A., Fauchier L., Vourc'h P., et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. JAm Coll Cardiol 2013, 61:2079-2087.
29. Banerjee A., Fauchier L., Vourc'h P., et al. Aprospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014, 145:1370-1382.
30. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:2599-2604.
31. McGrath E.R., Kapral M.K., Fang J., et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology 2013, 81:825-832.
32. Kishore A., Vail A., Majid A., et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014, 45:520-526.
33. Seet R.C., Friedman P.A., Rabinstein A.A. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011, 124:477-486.
34. Culebras A., Messe S.R., Chaturvedi S., Kase C.S., Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2014, 82:716-724.
35. Hart R.G., Diener H.C., Coutts S.B., et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014, 13:429-438.
36. Higgins P., MacFarlane P.W., Dawson J., et al. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke 2013, 44:2525-2531.
37. Sanna T., Diener H.C., Passman R.S., et al. Cryptogenic stroke and underlying atrial fibrillation. NEngl J Med 2014, 370:2478-2486.
38. Wachter R., Weber-Kruger M., Seegers J., et al. Age-dependent yield of screening for undetected atrial fibrillation in stroke patients: the Find-AF study. JNeurol 2013, 260:2042-2045.
39. Wallmann D., Tuller D., Wustmann K., et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke 2007, 38:2292-2294.
40. Kochhauser S., Dechering D.G., Dittrich R., et al. Supraventricular premature beats and short atrial runs predict atrial fibrillation in continuously monitored patients with cryptogenic stroke. Stroke 2014, 45:884-886.
41. Weber-Kruger M., Groschel K., Mende M., et al. Excessive supraventricular ectopic activity is indicative of paroxysmal atrial fibrillation in patients with cerebral ischemia. PLoS One 2013, 8:e67602.
42. Glotzer T.V., Daoud E.G., Wyse D.G., et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009, 2:474-480.
43. Healey J.S., Connolly S.J., Gold M.R., et al. Subclinical atrial fibrillation and the risk of stroke. NEngl J Med 2012, 366:120-129.
44. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
45. Brambatti M., Connolly S.J., Gold M.R., et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014, 129:2094-2099.
46. Daoud E.G., Glotzer T.V., Wyse D.G., et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of trends. Heart Rhythm 2011, 8:1416-1423.
47. Healey J.S., Martin J.L., Duncan A., et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: Prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol 2013, 29:224-228.
48. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542.
49. Reddy V.Y., Doshi S.K., Sievert H., et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013, 127:720-729.
50. Decker W.W., Stead L.G. Selecting rate control for recent-onset atrial fibrillation. Ann Emerg Med 2011, 57:32-33.
51. Stiell I.G., Birnie D. Managing recent-onset atrial fibrillation in the emergency department. Ann Emerg Med 2011, 57:31-32.
52. Rogenstein C., Kelly A.M., Mason S., et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department. Acad Emerg Med 2012, 19:1255-1260.
53. Stiell I.G., Macle L. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can J Cardiol 2011, 27:38-46.
54. Michael J.A., Stiell I.G., Agarwal S., Mandavia D.P. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999, 33:379-387.
55. Burton J.H., Vinson D.R., Drummond K., et al. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med 2004, 44:20-30.
56. Gallagher M.M., Hennessy B.J., Edvardsson N., et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. JAm Coll Cardiol 2002, 40:926-933.
57. Stiell I.G., Clement C.M., Perry J.J., et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM 2010, 12:181-191.
58. Xavier Scheuermeyer F., Grafstein E., Stenstrom R., et al. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med 2010, 17:408-415.
59. Airaksinen K.E., Gronberg T., Nuotio I., et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FINCV (Finnish Cardioversion) study. JAm Coll Cardiol 2013, 62:1187-1192.
60. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. NEngl J Med 1997, 336:1506-1511.
61. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e326S-e350S.
62. Thrombosis Canada. Peri-operative management of patients who are receiving warfarin. Available at: . Accessed May 13, 2014. http://www.thrombosiscanada.ca/guides/pdfs/Warfarin_perioperative_management.pdf.
63. Birnie D.H., Healey J.S., Wells G.A., et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. NEngl J Med 2013, 368:2084-2093.
64. Patatanian E., Fugate S.E. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother 2006, 40:2205-2210.
65. Siegal D., Yudin J., Kaatz S., et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012, 126:1630-1639.
66. PERIOP 2-A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin. Available at: . Accessed June 30, 2014. http://clinicaltrials.gov/show/NCT00432796.
67. Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study). Available at: . Accessed June 30, 2014. http://clinicaltrials.gov/show/NCT00786474.
68. Beyer-Westendorf J., Gelbricht V., Forster K., et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014, 35:1888-1896.
69. Healey J.S., Eikelboom J., Douketis J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012, 126:343-348.
70. Lopes R.D., Garcia D., Wojdyla D., et al. Use of apixaban and warfarin in patients undergoing invasive procedures: insights from Aristotle. Can J Cardiol 2013, 29:S232-S233.
71. Eliquis product monograph, l3 version 1.1. Available at: . Accessed June 30, 2014. http://www.pfizer.ca/en/our_products/products/monograph/313.
72. Pradax product monograph. Available at: . Accessed June 30, 2014. http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdf.
73. Kubitza D., Becka M., Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
74. Gillis A.M., Verma A., Talajic M., Nattel S., Dorian P. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011, 27:47-59.
75. Morillo C.A., Verma A., Connolly S.J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014, 311:692-700.
76. Whitbeck M.G., Charnigo R.J., Khairy P., et al. Increased mortality among patients taking digoxin-analysis from the affirm study. Eur Heart J 2013, 34:1481-1488.
77. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013, 34:1489-1497.
78. Vallakati A., Chandra P.A., Pednekar M., Frankel R., Shani J. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther 2013, 20:e717-e719.
79. Kirchhof P., Andresen D., Bosch R., et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (flec-sl): a prospective, randomised, open-label, blinded end point assessment trial. Lancet 2012, 380:238-246.
80. Cosedis Nielsen J., Johannessen A., Raatikainen P., et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. NEngl J Med 2012, 367:1587-1595.
81. Packer D.L., Kowal R.C., Wheelan K.R., et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic front (STOP AF) pivotal trial. JAm Coll Cardiol 2013, 61:1713-1723.
82. Andrade J.G., Khairy P., Guerra P.G., et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm 2011, 8:1444-1451.
83. Schmidt M., Dorwarth U., Andresen D., et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German ablation registry. JCardiovasc Electrophysiol 2014, 25:1-7.
84. Calkins H., Reynolds M.R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009, 2:349-361.
85. Hummel J., Michaud G., Hoyt R., et al. Phased RF ablation in persistent atrial fibrillation. Heart Rhythm 2014, 11:202-209.
86. Herrera Siklody C., Deneke T., Hocini M., et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation comparison of different atrial fibrillation ablation technologies in a multicenter study. JAm Coll Cardiol 2011, 58:681-688.
87. Gaita F., Leclercq J.F., Schumacher B., et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. JCardiovasc Electrophysiol 2011, 22:961-968.
88. Verma A., Debruyne P., Nardi S., et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the Evaluation of Reduction of Asymptomatic Cerebral Embolism trial. Circ Arrhythm Electrophysiol 2013, 6:835-842.
89. Hoyt H., Bhonsale A., Chilukuri K., et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011, 8:1869-1874.
90. Shah R.U., Freeman J.V., Shilane D., et al. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. JAm Coll Cardiol 2012, 59:143-149.
91. Deshmukh A., Patel N.J., Pant S., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013, 128:2104-2112.
92. Gupta A., Perera T., Ganesan A., et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol 2013, 6:1082-1088.
93. Green M.S., Guerra P.G., Krahn A.D. 2010 Canadian Cardiovascular Society/Canadian Heart Rhythm Society training standards and maintenance of competency in adult clinical cardiac electrophysiology. Can J Cardiol 2011, 27:859-861.
94. Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008, 118:2498-2505.
95. Packer D.L., Irwin J.M., Champagne J., et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front Stop-AF pivotal trial. JAm Coll Cardiol 2010, 55:E3015-E3016.
96. Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (catheter ablation for the cure of atrial fibrillation study). Eur Heart J 2006, 27:216-221.
97. Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010, 303:333-340.
98. Piccini J.P., Lopes R.D., Kong M.H., et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009, 2:626-633.
99. Weerasooriya R., Khairy P., Litalien J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. JAm Coll Cardiol 2011, 57:160-166.
100. Tzou W.S., Marchlinski F.E., Zado E.S., et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:237-242.
101. Ganesan A.N., Shipp N.J., Brooks A.G., et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. JAm Heart Assoc 2013, 2:e004549.
102. Vogt J., Heintze J., Gutleben K.J., et al. Long-term outcomes after cryoballoon pulmonary vein isolation: results from a prospective study in 605 patients. JAm Coll Cardiol 2013, 61:1707-1712.
103. Di Biase L., Burkhardt J.D., Mohanty P., et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010, 121:2550-2556.
104. Santangeli P., Di Biase L., Horton R., et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012, 5:302-311.
105. Di Biase L. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "compare" randomized trial (abstract LB01-1). Heart Rhythm Society 2013 scientific sessions; May 09, 2013 2013, Denver, CO.
106. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. JAm Coll Cardiol 2012, 59:1168-1174.
107. Kim J.S., She F., Jongnarangsin K., et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013, 10:483-489.
108. Bassiouny M., Saliba W., Rickard J., et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013, 6:460-466.
109. Providencia R., Albenque J.P., Combes S., et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014, 100:324-335.
110. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. JAm Coll Cardiol 2014, 63:982-988.
111. Tsuchiya T. Can we stop warfarin after AF ablation?. Circ J 2011, 75:2312-2313.
112. Hunter R.J., McCready J., Diab I., et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012, 98:48-53.
113. Reynolds M.R., Gunnarsson C.L., Hunter T.D., et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes 2012, 5:171-181.
114. Bunch T.J., May H.T., Bair T.L., et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013, 10:1272-1277.
115. Verma A., Champagne J., Sapp J., et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013, 173:149-156.